Citigroup
RAPP

Citigroup’s Rapport Therapeutics RAPP Stock Holding History

Citigroup’s Portfolio RAPP Stock Details RAPP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.47M Buy
78,799
+22,315
+40% +$628K ﹤0.01% 2531
2025
Q4 		$1.71M Buy
56,484
+54,714
+3,091% +$1.51M ﹤0.01% 2763
2025
Q3 		$52.6K Sell
1,770
-5,283
-75% -$94.2K ﹤0.01% 4478
2025
Q2 		$80.2K Sell
7,053
-8,032
-53% -$85.2K ﹤0.01% 4523
2025
Q1 		$151K Buy
15,085
+5,508
+58% +$71.5K ﹤0.01% 4351
2024
Q4 		$170K Sell
9,577
-3,197
-25% -$70.8K ﹤0.01% 4510
2024
Q3 		$262K Buy
+12,774
New +$274K ﹤0.01% 4158

Other funds holding RAPP

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
TGV
TRV GP V Boston, Massachusetts $401M AUM 284.76% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return

Citigroup's RAPP Position: Q1 2026 in Review

Citigroup increased its Rapport Therapeutics (RAPP) stake by 40% in Q1 2026, buying an estimated $628K and bringing the position to 78,799 shares worth $2.47M. The position accounts for ﹤0.01% of the portfolio, ranked #2531.

Citigroup first reported a position in RAPP in Q3 2024 and has held it in 7 quarters since. 147 funds tracked by Wall St. Rank hold RAPP as of Q1 2026.

  • Citigroup held 78,799 shares of Rapport Therapeutics worth $2.47M as of Q1 2026.
  • Citigroup bought 22,315 Rapport Therapeutics shares in Q1 2026, an estimated $628K.
  • Rapport Therapeutics made up ﹤0.01% of Citigroup's portfolio in Q1 2026, its #2531 holding.
  • Citigroup first reported a position in Rapport Therapeutics in Q3 2024 and has held it in 7 quarters since.
  • 147 funds tracked by Wall St. Rank held Rapport Therapeutics as of Q1 2026.

Based on Citigroup's 13F filing for Q1 2026, filed 11 May 2026.